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Abstract.  Brefeldin A  (BFA) causes rapid redistribu- 
tion of Golgi proteins into the ER, leaving no defina- 
ble Golgi apparatus,  and blocks transport of proteins 
into post-Golgi compartments in the cell. In this study 
we follow the disassembly of the Golgi apparatus in 
BFA-treated, living ceils labeled with NBD-ceramide 
and demonstrate that forskolin can both inhibit and re- 
verse this process. Long, tubular processes labeled 
with NBD-ceramide were observed emerging from Golgi 
elements and extending out to the cell periphery in 
cells treated with BFA for 5 min.  With longer incuba- 
tions in BFA, the NBD label was dispersed in a  fine 
reticular pattern characteristic of the ER.  Treatment 
with forskolin inhibited these effects of BFA as well as 
BF,¢s earliest morphologic effect on the Golgi appara- 
tus: the redistribution to the cytosol of a  ll0-kD 
Golgi peripheral membrane protein.  In addition,  for- 
skolin could reverse BF,~s block in protein secretion. 
Forskolin inhibition of BFgs effects was dose depen- 
dent and reversible. High concentrations of BFA could 
overcome forskolin's inhibitory effect, suggesting for- 
skolin and BFA interact in a competitive fashion.  Re- 
markably, in cells already exposed to BFA, forskolin 
could reverse BF,~s effects causing the  l l0-kD Golgi 
peripheral membrane protein to reassociate with Golgi 
membrane and juxtanuclear Golgi complexes to reas- 
semble. Neither membrane permeant cAMP analogues 
nor cAMP phosphodiesterase inhibitors could replicate 
or enhance forskolin's inhibition  of BFA.  1,9-Dideoxy- 
forskolin, which does not activate adenylyl cyclase, 
was equally as effective as forskolin in antagonizing 
BFA. A derivative of forskolin, 7-HPP-forskolin, that 
is less potent than forskolin at binding to adenylyl cy- 
clase, was also equally effective as forskolin in an- 
tagonizing BFA. In contrast a  similar derivative, 
6-HPP-forskolin, that is equipotent with forskolin at 
binding to adenylyl cyclase, did not inhibit BFgs 
effects.  These results suggest that forskolin acts as a 
competitive antagonist to BFA, using a cAMP-inde- 
pendent mechanism to prevent and reverse the mor- 
phologic effects induced by BFA. 
T 
wo  fundamental  questions in cell biology are how 
membrane organelles of  the secretory system maintain 
their  identity  and  how  selective  transport  between 
these organelles  is achieved.  In vitro reconstitution  of in- 
terorganelle  transport  (Balch  et al.,  1984;  Beckers et al., 
1987),  and the application  of yeast genetics  for the iden- 
tification  of specific genes required for movement through 
the secretory pathway (Schekman, 1985) are two lines of re- 
search that are beginning to illuminate the biochemical basis 
for selective interorganelle  transport.  These approaches have 
revealed integral components of the secretory transport ma- 
chinery but have yet to define the molecular basis of or- 
ganelle  identity.  The  finding  that  the  drug  brefeldin  A 
(BFA)  ~  has pronounced effects on both transport out of and 
1.  Abbreviations used in this paper:  BFA, brefeldin A; IBMX, isobutyl 
methylxanthinc; Man 1I, mannosidase II. 
the existence  of the Golgi apparatus  has provided an addi- 
tional  approach for addressing  the questions of organelle 
identity  and selective membrane transport. 
Three phenotypic changes  are seen in cells exposed to 
BFA: (a) protein transport within the secretory pathway be- 
yond the Golgi apparatus  is blocked (Misumi  et al.,  1986; 
Oda et al., 1987); (b) the Golgi apparatus  rapidly disassem- 
bles and no longer exists as a distinct cellular compartment 
(Fujiwara  et al.,  1988;  Lippincott-Schwartz  et al.,  1989); 
and (c) resident and itinerant Golgi proteins, as well as Golgi 
lipid,  are redistributed into the ER (Lippincott-Schwartz  et 
al., 1989; Doms et al., 1989; Young et al., 1990). Whether 
all these phenotypic changes are the result of the perturba- 
tion of a single molecular target remains to be established. 
BFb2s effects, however, fulfill a variety of criteria for the type 
of pharmacologic tool that might yield insight into the mech- 
anisms  underlying  organdie  identity  and  interorganelle 
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apparatus and are rapidly and completely reversed by remov- 
ing the drug (Misumi et al.,  1986;  Lippincott-Schwartz  et 
al.,  1989; Fujiwara et al.,  1989). In addition, disruption of 
the Golgi apparatus by BFA occurs at relatively low concen- 
trations (50-100 nM). Finally, minor chemical modifications 
of BFA completely abrogate its cellular effects (Donaldson, 
J. G., J. Lippincott-Schwartz, and R. Klausner, unpublished 
observations). 
Previous studies with BFA have detailed the phenotypic 
changes  within  cells as  a  consequence of BFA  treatment 
using morphological and biochemical techniques.  Resident 
membrane proteins of the cis-, medial, and trans-Golgi sys- 
tem have been observed to redistribute rapidly into the ER 
after  treatment  of cells  with  BFA  in  contrast  to  compo- 
nents  of the  trans-Golgi  network  (Fujiwara  et al.,  1989; 
Lippincott-Schwartz et al.,  1989,  1990; Chege and Pfeffer, 
1990). As a consequence of this, carbohydrate side chains 
of resident  or retained  proteins  in  the  ER are  processed 
as  if they  have  been  transported  to  the  Golgi  complex 
(Lippincott-Schwartz et al., 1989; Doms et al., 1989; Ulmer 
and Palade,  1989). Although no definable Golgi structures 
remain in ceils exposed to BFA (Fujiwara et al., 1988), once 
BFA is removed Golgi proteins rapidly sort out of the ER and 
a  recognizable  Golgi  apparatus  is  reformed  (Lippincott- 
Schwartz et al.,  1989). 
Recent studies with BFA have identified specific biochemi- 
cal changes of the Golgi apparatus in cells treated with this 
compound.  Donaldson et al.  (1990) observed rapid altera- 
tion in the intracellular localization of a ll0-kD cytoplasmi- 
cally oriented, peripheral membrane protein of the Golgi ap- 
paratus  (Allan and Kreis,  1986) upon addition  of BFA to 
ceils. Within 30 s of BFA treatment, the intracellular location 
of the ll0-kD protein shifted from a Golgi distribution to a 
diffuse cytoplasmic pattern. This shift preceded all other ob- 
servable morphologic  changes in the Golgi apparatus  and 
was reversible.  Upon removal of BFA, the  ll0-kD protein 
rapidly reassociated with newly forming Golgi structures. 
These observations point to the presence of critical mole- 
cules  (i.e.,  the  molecular  targets  of BFA)  that  must  be 
regulating  and maintaining  both the structure of the Golgi 
apparatus  and  its  ability  to allow anterograde  membrane 
transport.  Deciphering  how BFA is working  in cells ulti- 
mately will require the identification of BF/fs binding site(s). 
An important step toward this goal is the understanding  of 
the structure and function of BFA through the identification 
of drugs that either mimic, antagonize, or alter the effects of 
BFA. We report here on one such reagent, the naturally oc- 
curring diterpine, forskolin, which initially was observed to 
interfere with BF/Cs effects by J. Glickman and M. Sheetz. 
Forskolin is known to have multiple effects on cells, in- 
cluding stimulation of the enzyme adenylyl cyclase, leading 
to a dramatic rise in cAMP levels in ceils (Seamon and Daly, 
1986), and the cAMP independent inhibition of both mem- 
brane  transport  and  channel  proteins  (Laurenza  et  al., 
1989). In this paper we demonstrate that forskolin can inhibit 
and reverse BF~2s  morphologic effects on the Golgi apparatus 
using the vital stain N-(7-(4-nitrobenzo-2-oxa-l,3-diazole))- 
6-aminocaproylsphingosine  (NBD-ceramide)  and  antibod- 
ies to the cis/medial Golgi enzyme mannosidase II (Man II), 
as markers for the Golgi complex. Forskolin inhibition and 
reversal of BFA action occurred in a competitive manner by 
a  mechanism  that  was  cAMP independent.  These  results 
suggest forskolin acts as a competitive antagonist to BFA, 
making it a useful probe for the dissection of the mechanism 
by  which  BFA  disrupts  Golgi  structure  and  membrane 
trafficking. 
Materials and Methods 
Materials and Cells 
NRK (normal rat kidney) cells were maintained at 37"C in RPMI  1640 
medium supplemented with 10% fetal calf serum, 2 mM glutamine, peni- 
cillin, and streptomycin. TCRoKiPI  cells were a kind gift of Mark Davis 
(Stanford University, CA) and were developed as described in Lin et al. 
(1990).  Cells were grown on 12-mm round glass coverslips for 1-2 days be- 
fore use. 
Brefeldin A was either purchased from Epicentre Technologies (Madi- 
son, WI) or obtained from Sandoz Ltd. (Basel, Switzerland). It was stored 
at -20°C as a stock solution of I mg/ml in methanol. NBD ceramide was 
obtained from Molecular Probes Inc. (Eugene, OR) and was stored as a 
solid at -20°C or as 200 nmol/rni stock in 2:1 chloroform/methanol at 4°C. 
Forskolin, dibutyryl cAMP, and IBMX were of highest available grade and 
were  purchased  from  Sigma  Chemical  Co.  (St.  Louis,  MO).  6-HPP- 
forskolin, and 7-HPP-forskolin were prepared according to Robbins, J., A. 
Lanrenza, G.  O.  O'Mailey, B.  Spahl, R.  W.  Kosley,  and K. B.  Seamon 
(manuscript submitted for publication).  1,9-Dideoxyforskolin was  pur- 
chased from Caibiochem-Behring Corp., San Diego, CA. 
Antibodies 
Rabbit IgG directed against Golgi Man I1 (Moremen and Touster,  1985) was 
the kind gift of Dr. K. Moremen (Massachusetts Institute of Technology, 
Cambridge, MA). The mouse monoclonal antibody M3A5 recngnizes the 
ll0-kD Golgi peripheral membrane protein (Allan and Kreis, 1986).  The 
mouse monoclonal antibody, A2B4-2, binds to the TCR~ chain (Samelson 
et al., 1983). Rhodamine- and fluorescein-labeled  goat anti-mouse and goat 
anti-rabbit IgG were purchased from Organon-Teknika  (Westchester, PA) 
and used at 1:500  dilution of manufacturer's stock solution. 
NBD-Ceramide Labeling of Cells 
NBD-ceramide-BSA conjugates were prepared in the appropriate serum- 
free medium according to Lipsky and Pagano (1985).  Cells plated on glass 
coverslips  were washed once with serum-free medium, incubated for 10 rain 
at 37°C with NBD-ceramide-BSA, and washed three times with complete 
media (5 rain at 37°C for each wash). Labeled cells were maintained at 
37°C until use and were used within'30-45 rain of labeling. Images of la- 
beled cells were obtained using the fluorescein channel on a Zeiss micro- 
scope. 
Immunofluorescence Microscopy 
NRK cells were grown on No. 1 glass coverslips to 60-70% confluency. Af- 
ter appropriate incubation conditions, the ceils were fixed for 10 min at 
room temperature in 2% formaldehyde in PBS and washed in PBS contain- 
ing  10%  fetal calf serum. For permeabilization, cells were incubated in 
methanol at 0°C for l rain and then rinsed in PBS/10% serum. Cells were 
incubated in primary antibody in PBS/serum and 0.2%  saponin for 1 h, 
washed free of antibody in PBS/serum, and then incubated in fluorescently 
labeled secondary antibody in PBS/serum/0.2% saponin for 1 h. After a 
final washing in PBS/serum and then PBS alone the cells were mounted onto 
glass slides in fluoromount G  (Southern Biotechnolngy Associates), and 
viewed with a 63x  oil planapo lens on a Zeiss microscope equipped with 
barrier filters to prevent crossover of fluorescein and rhodamine fluores- 
cence. 
Metabolic Labeling and Immunoprecipitation 
For  metabolic  labeling,  cells were preincubated for 5  min at  37°C  in 
methionine-free medium containing  10%  fetal bovine serum.  The cells 
were then labeled for 30 rain with 0.25  mCi/ml [35S]methionine  (Trans- 
3sS-label;  ICN Biomedicals, Inc., Irvine, CA) in methionine-free medium 
containing 10%  fetal bovine serum. At the end of the pulse, radioactive 
medium was removed and the cells were chased in complete medium for 
2 h. The chase was terminated by placing the cells on ice. Solubilization 
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Digestion  with  the enzyme  endo  H (Genzyme,  Boston, MA) was performed 
by incubating  the immunoprecipitates  for 16 h at 37°C with  5 mU of  endo H 
in 50/zl of  0.1 M sodium phosphate  buffer (pH 6.1) containing 0.1% Triton 
X-100, 0.03 M SDS, and 20 mM EDTA. 
Figure 1.  Effects of BFA and forskolin on the morphology  of the 
Golgi apparatus  in living NRK cells stained with the fluorescent 
lipid NBD-ceramide. NRK cells were stained with NBD-ceramide 
and treated with nothing (Untreated), with 1/zg/ml BFA for 5 min 
(BFA, 5 min), with 0.1/~g/ml BFA for 30 min (BFA, 30 min), with 
100 ttM forskolin for 1 h (forskolin), or with 100 #M forskolin for 
30 min and then forskolin (100/zM) plus BFA (0.1 mg/ml) for 30 
man (forskolin + BFA).  Living cells were viewed by  fluorescence mi- 
croscopy using fluorescein optics. In untreated  cells,  NBD-cera- 
mide-labeled  Golgi  structures  appeared  as juxtanuclear,  tightly 
packed cisternae. Treatment of cells with BFA for 5 min caused the 
cisternae to enlarge and to extend thin, tubular processes out to the 
cell periphery  (BFA, 5 rain). After 30 min of BFA treatment,  the 
NBD-ceramide label now appeared in a diffuse pattern with some 
accumulation in juxtanuclear  vesicles (BFA, 30 min). Pretreatment 
of cells with forskolin inhibited  BFA-induced dispersal  of NBD- 
ceramide (forskolin + BFA), while treatment with forskolin alone 
had  no effect on the  Golgi  distribution  of NBD-cerarnide.  Bar, 
10 p,m. 
and immunoprecipitation  using antibody adsorbed to protein A-agarose 
(Bethesda Research Laboratories, Gaithersburg, MD) were performed  as 
previously described (Lippineott-Schwartz  et al., 1988). Immunoprecipi- 
tated proteins were analyzed  by SDS-PAGE  on polyaerylamide  gels (13%) 
Results 
Effects of BFA on the Membranes of the Col# 
Apparatus in Living Cells 
Previous work has demonstrated that BFA causes the rapid 
and reversible redistribution of Golgi resident and itinerant 
proteins  into  the  ER  (Lippincott-Schwartz  et  al.,  1989; 
Doms et al.,  1989; Fujiwara et al.,  1989). To determine the 
fate of Golgi membranes in BFA-treated cells we examined 
the effect of this drug on the distribution of the fluorescent 
lipid  NBD-ceramide,  which  specifically  associates  with 
Golgi membranes of living cells (Lipsky and Pagano, 1985), 
Since the NBD-ceramide label remains associated with the 
Golgi apparatus for 2-3 h and can be easily visualized with 
fluorescence optics, this system is excellent for monitoring 
movement of Golgi membranes in  living cells (Ho et al., 
1989;  Cooper et al.,  1990). 
In  untreated  NRK  cells,  NBD-ceramide  strongly  and 
specifically labeled a  perinuclear membrane compartment 
(Fig.  1,  Untreated)  which previously has been shown to be 
the  Golgi apparatus by double labeling  with  markers for 
Golgi-specific proteins  (Lipsky  and  Pagano,  1985).  The 
NBD-ceramide-labeled Golgi complex in NRK cells ranged 
in appearance from elongated, interconnected networks to a 
tightly massed ring or half ring surrounding the nucleus. Ad- 
dition of BFA to the cells had a rapid and striking effect on 
the morphology of the NBD-ceramide-labeled Golgi com- 
plex.  Within  5  min of BFA treatment at 37°C,  numerous 
long, thin tubular processes extending out of  brightly-stained 
and  enlarged Golgi structures  were evident  (Fig.  1,  BFA, 
5 min). These processes appeared as continuous tubules that 
extended up to 10 ~m from Golgi elements. By 30 rain, the 
Golgi label was dispersed in a fine reticular pattern through- 
out the cell (Fig.  1, BFA, 30 min). In some cells, in addition 
to this dispersed pattern, numerous small vesicles in a jux- 
tanuclear  location were  labeled  with  the  fluorescent dye. 
However, no fluorescence in large Golgi-like structures re- 
mained.  These results  with  NBD-ceramide in  living cells 
closely  parallel  the  morphological  changes  observed  for 
Golgi resident proteins during BFA treatment (Lippincott- 
Schwartz et al.,  1990).  Thus, Golgi lipid appears to share 
the fate of resident Golgi proteins upon BFA treatment. 
Effects of Forskolin on the Distribution of 
NBD-Ceramide in BFA-treated Cells 
Since  many  cellular  functions  are  under  the  regulatory 
influence of cAMP, and cAMP-dependent protein kinase II 
has been localized to the Golgi apparatus (Nigg et al., 1985), 
we wondered whether BF~s effects on Golgi structure and 
dynamics is either due to or regulated by changes in cellular 
cAMP levels.  To explore this possibility we examined the 
effect of forskolin, an activator of adenylyl cyclase, on BFgs 
action. As shown in Fig.  1 (forskolin + BFA), pretreatment 
of cells with 100 t~M forskolin for 30 min before addition of 
0.1/zg/ml BFA for 30 min resulted in no change in morphol- 
Lippincott-Schwartz  et al. Forskolin  Inhibits BFA's Effects on Golgi  569 Figure 2. Dose response to forskolin in BFA-treated cells. NRK cells were treated with O (A),  10 (B), 25 (C), 50 (D), 100 (E), or 200 
/zM (F) forskolin for 30 min at 37°C. BFA (0.1/~g/ml) was then added to the cells for an additional 1-h incubation in the continued presence 
of forskolin. The cells were then fixed, permeabilized,  and stained for immunofluorescence using antibodies to Man II. At 0.1/~g/ml BFA 
(.4), Man II labeling appeared only in the nuclear envelope and in a diffuse reticular pattern due to disassembly of the Golgi apparatus 
induced by BFA. Preincubation of cells with forskolin at concentrations at and above 50/~M (D, E, and F) before BFA treatment inhibited 
Golgi disassembly. At these concentrations of forskolin, Man 1I appeared in normal looking juxtanuclear  Golgi structures. Man II staining 
in cells treated with  10 (B) or 25 ~,M (C) forskolin before BFA treatment  showed diffuse ER staining in addition to staining of distinct 
vacuoles and tubular processes.  Bar, 10 #m. 
ogy of the Golgi apparatus.  Since cells treated for 30 rain 
with  0.1  /~g/ml  BFA  alone  showed  dispersal  of  NBD- 
ceramide from perinuclear Golgi structures  into  a  diffuse 
ER-like network (Fig.  1, BFA, 30 min),  these results sug- 
gested  that  forskolin  could  inhibit  BF~Cs effects on  Golgi 
morphology. Removal of forskolin in the continued presence 
of BFA resulted in rapid dispersal of NBD-labeled Golgi ele- 
ments and the  redistribution  of the NBD label into a  fine 
ptmctate  ER-like  pattern  indicating  forskolin's  inhibitory 
effects on BFA were reversible (data not shown).  Forskolin 
treatment alone had very little effect on the distribution of 
NBD-ceramide within cells (Fig.  1, forskolin).  If anything, 
the  Golgi  apparatus  was  more brightly  stained  by  NBD- 
ceramide in forskolin-treated cells and appeared more com- 
pact than in control cells. 
Forskolin Acts as a Competitive Antagonist to BFA's 
Effect on the Golgi Apparatus 
We sought to determine whether forskolin acted at the same 
site as BFA or at an independent target distal to the BFA tar- 
get. To distinguish between these possibilities, we examined 
the  concentration  dependence  of  forskolin's  inhibition  of 
BFA using antibodies to the cis/medial Golgi enzyme, Man 
II, as marker for the Golgi apparatus. As shown in Fig. 2 A, 
cells treated with 0.1  ~tg/ml  BFA alone for  1 h  showed no 
staining of Golgi structures.  Instead, Man II was localized 
in the nuclear envelope and in a diffuse reticular pattern that 
previously has been shown by immunoelectron microscopy 
and biochemical techniques to include their distribution in 
the ER (Lippincott-Schwartz et al.,  1989).  Cells pretreated 
The Journal of Cell Biology, Volume 112,  1991  570 Figure 3.  Dose response to BFA in forskolin-treated cells. NRK cells were treated with or without 100 #M forskolin for 30 min at 37°C. 
BFA at the noted concentrations was then added for an additional 1 h. The cells were then fixed, permeabilized, and stained with Man 
II antibodies for immunofluorescence. At low concentrations of  BFA (0.001 #g/ml), Man II labeling appeared in Golgi cisternae surrounding 
the nucleus. Addition of BFA at concentrations of 0.05/~g/ml or higher caused Man II to redistribute into a fine punctate/reticular pattern 
characteristic of ER labeling. Pretreatment of cells with forskolin shifted the concentration of BFA required to observe Man II redistribution 
into the ER to >0.5 #g/ml. Bar,  10 #m. 
Figure 4. Forskolin inhibits BFA-induced dissociation of the 110-kD protein from the Golgi apparatus. NRK cells were treated with nothing 
(Untreated),  with BFA (0.1 gg/ml) for 20 rain (BFA), with forskolin (100/zM) for 1 h (Forskolin), or treated with forskolin (100/zM) for 
min and then BFA (0.1 /~g/ml) plus forskolin (100/~M) for an additional 20 min (Forskolin  +  BFA),  all at 37°C. The cells were fixed, 
permeabilized, and stained by double-label immunofluorescence with antibodies to Man II and the ll0-kD protein. In untreated cells, 
Man II was localized to the Golgi apparatus which appeared as a compact, perinuclear structure in these cells. The distribution of the 
110-kD protein colocaiized with Man H labeling of the Golgi apparatus but also occurred in peripheral vesicles. After 20 min of BFA 
(0.1 ~g/ml) treatment, the ll0-kD protein was widely scattered throughout the cytoplasm, while Man II remained largely associated with 
the Golgi apparatus due to the low concentrations of BFA used. At these concentrations of BFA both the dissociation of the ll0-kD protein 
and subsequent redistribution of Golgi membrane into the ER are not as rapid as occurs with higher concentrations of BFA (i.e., 5/~g/ml 
and greater) (see Donaldson et al., 1991). Pretreatment of cells with forskolin (100 gM) before the'addition of BFA prevented BFA-induced 
dissociation of the ll0-kD protein from the Golgi apparatus. Forskolin treatment alone had no noticeable effect on the distributions of 
Man II or the  110-103 protein compared to untreated cells. Bar,  10 #m. 
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the addition of 0.1  gg/ml  BFA,  however,  showed a  dose- 
dependent inhibition of Golgi apparatus dispersal. Low con- 
centrations of forskolin (10/zM) had only a slight inhibitory 
effect  on BFA-induced Golgi redistribution into the ER (Fig. 
2 B). At this concentration of forskolin, Man II appeared in 
distinct vesicles surrounding the nucleus in addition to a 
diffuse reticular pattern. At 25/zM forskolin, more distinct 
Golgi-like structures were apparent in the BFA-treated cells 
and tubular elements were frequently seen extending out of 
these structures (Fig. 2  C).  At concentrations of forskolin 
/>50 gM (Fig. 2, D, E, and F) pronounced inhibition of  BF/~s 
effects was observed. At these concentrations of forskolin, 
essentially normal Golgi structures were observed. Longer 
incubation times at these higher concentrations of forskolin 
(100 and 200/zM) showed no delayed effect  of BFA on Golgi 
morphology (not shown). 
If forskolin acted at a site distinct from the site of BFA ac- 
tion then raising the concentration of  BFA at an effective  dose 
of forskolin would not be expected to overcome forskolin's 
effects. If, however, forskolin acted at the same site as BFA, 
raising the concentration of BFA might be expected to over- 
come forskolin's inhibitory effects. A dose-response curve of 
BFA in the presence of 100 gM forskolin was performed to 
distinguish between these possibilities. As shown in Fig. 3, 
rather than inhibit BFNs effects at all concentrations of BFA, 
100 #M forskolin appeared only to shift the dose dependence 
of BFA action. Whereas 50 ng/ml BFA was normally suf- 
ficient to  cause  Golgi  apparatus  dispersal  in  NRK  cells, 
>500 ng/ml BFA was required to achieve the same result in 
the presence of 100 #M forskolin. These results suggested 
that forskolin and BFA act in a competitive fashion. 
Forslmlin Inhibits BFA's Earliest Effects on the 
Golgi Apparatus 
We have previously shown that within minutes of BFA treat- 
ment Golgi morphology is affected (Lippincott-Schwartz et 
ai.,  1990).  In addition to spreading numerous,  long,  thin 
membrane processes, the Golgi complex itself is altered in 
appearance: the normal compact and flattened cisternal ele- 
ments become replaced by numerous vacuoles.  Recently, 
Donaldson et al.  (1990)  have reported that a  llO-kD  cy- 
toplasmically  oriented  peripheral  membrane  protein  re- 
distributes to the cytosol within 30 s of adding 5/~g/ml BFA 
to cells. This precedes all other morphologic changes ob- 
servable at the light microscope level in BFA-treated cells. 
The kinetics of dissociation of the ll0-kD protein and move- 
ment of Man II into the ER in BFA-treated cells was found 
to be dose dependent. With lower concentrations of  BFA, the 
110-kD protein took longer to dissociate from the Golgi ap- 
paratus and subsequent transport of Golgi proteins into the 
ER  was  slower  (Donaldson  et  al.,  1990).  To  determine 
whether forskolin's inhibition of BFNs effects extended to 
the ll0-kD protein, we examined the effect of forskolin on 
the dissociation of the 110-kD protein using antibodies to the 
110-kD protein. In control  cells, the distribution of  the 11O-kD 
protein significantly overlapping with Man II staining of the 
Golgi apparatus in the same cell (Fig. 4,  Untreated). The 
l l0-kD protein, however, appeared less tightly associated 
with cisternal Golgi elements compared to Man II, and also 
appeared to be associated with peripheral vesicles. Forskolin 
treatment alone had very little effect on the distribution of 
both the  ll0-kD  protein and  Man  II  (Fig.  4,  Forskolin). 
Treatment with 0.1 gg/ml BFA for 20 min, however, caused 
the ll0-kD protein to dissociate from the Golgi apparatus 
and to distribute into a diffuse punctate pattern throughout 
the cytoplasm (Fig. 4, BFA). Due to the low concentration 
of BFA used in this experiment, Man II remained predomi- 
nantly in perinuelear Golgi structures at this time of BFA 
treatment. Upon longer incubations with BFA (i.e., 30-60 
rnin), Man II no longer appeared in Golgi structures and in- 
stead had redistributed into an ER-like pattern (see Fig. 6). 
The 110-kD protein retained its diffuse punctate pattern dur- 
ing longer BFA treatments and never colocalized with the 
Golgi marker. When cells were first treated with forskolin 
for 30 min and then BFA was added, remarkably no dissocia- 
tion of  the ll0-kD protein from perinuclear Golgi structures 
was observed (Fig. 4, Forskolin + BFA). The ll0-kD pro- 
tein remained associated with perinuclear Golgi structures 
at all times in cells treated with forskolin plus BFA including 
prolonged periods (data not shown). These results indicate 
forskolin  inhibits  BFNs  earliest  observable  effect on  the 
Golgi apparatus;  the dissociation of the ll0-kD peripheral 
Golgi membrane protein. 
Effect of  Forskolin on the Processing of  N-linked 
Oligosaccharide  Chains in BFA-treated Cells 
One consequence of the redistribution of Golgi proteins into 
the ER in BFA-treated cells is the modification of carbohy- 
drate chains of ER resident and retained proteins by Golgi 
enzymes. This effect on carbohydrate processing has been 
observed for a  variety of proteins (Lippincott-Schwartz et 
al.,  1989; Doms et al.,  1989; Ulmer and Palade,  1989). If 
forskolin inhibits BFA-induced redistribution of Golgi pro- 
Figure 5.  Forskolin abrogates BF/Cs effect on the  carbohydrate 
processing of ER retained proteins. NRK cells were pulse labeled 
with [35S]methionine for 30 rain and chased for 2 h with normal 
medium (Control), with 0.1 /~g/ml BFA (BFA), or with forskolin 
(100 ~M) alone for 15 min and then forskolin plus BFA (0.1 gg/ml) 
for 2 h (BFA + forskolin). The cells were detergent solubilized, im- 
munoprecipitated with anti-TCR a  chain antibodies, and treated 
with or without endo H before analysis by SDS-PAGE  under reduc- 
ing conditions. In control cells, TCRod3PI migrated on the gel at 
,o40 kD at the end of either the pulse or chase. Endo H digestion 
cleaved "I'CRoLGPI  to a faster migrating species. In the presence of 
BFA, TCRaGPI matured to a slightly higher molecular mass spe- 
cies that was largely resistant to cleavage by endo H. Treatment 
with forskolin plus BFA abrogated this effect of BFA and produced 
an endo H-sensitive form of TCRcxGPI  in the chase that was indis- 
tinguishable from control cells. 
The Journal of Cell Biology,  Volume 112, 1991  572 Figure 6. Addition of forskolin reverses the effects of BFA on the Golgi apparatus. NRK cells were treated with BFA (0.1 ttg/ml) for i h 
at 37°C. Forskolin (100 #M) was then added to the cells for 0, 30 rain, or 2 h at 37°C in the continued presence of BFA. After fixation 
and permeabilization, the cells were stained and prepared for double-label immunofluorescenee  using antibodies to Man II and the 110-kD 
protein. During BFA treatment alone (0), the ll0-kD protein and Man 1] were not localized to Golgi structures but instead were diffusely 
distributed in the cytosol or associated with ER membrane, respectively. Upon addition of forskolin, both proteins co-localized in distinct 
vesicles scattered throughout the cytoplasm (30 min) which later coalesced into juxtanuclear  Golgi-like structures (2 h). Bar, 10/zm. 
teins into the ER, as suggested by our morphologic observa- 
tions, than one would predict that Golgi processing of ER 
resident proteins would not occur in cells treated with BFA 
plus forskolin. To test this possibility we studied a truncated 
form of the T  cell antigen receptor alpha chain that lacks 
transmembrane and cytoplasmic peptide domains but con- 
tains a phosphatidyl inositol glycan linkage (TCRa43PI) (Lin 
et al.,  1990). When expressed in CHO cells, TCRotGPI is 
retained within the membranes of the ER throughout its life- 
time (Suzuki, C., manuscript submitted for publication). In 
these cells, because TCRo~3PI never reaches the Golgi ap- 
paratus its oligosaccharide chains remain sensitive to diges- 
tion  by  endoglycosidase H  (endo  H),  an  enzyme which 
cleaves "high mannose" but not "complex" type oligosaccha- 
rides (Tarentino and Maley,  1974; Kornfeld and Kornfeld, 
1985).  This is demonstrated in the metabolic labeling ex- 
periment of Fig. 5, where TCRaGPI appeared endo H sensi- 
tive after either a 30-min pulse or 2-h chase. In ceils exposed 
to  BFA  during  the  2-h  chase  period,  TCRog3PI became 
endo H resistant due to redistribution of Golgi enzymes into 
the ER. In cells treated with BFA plus forskolin during the 
2-h chase period, however, only endo H sensitive forms of 
TCRoLGPI  appeared,  consistent  with  forskolin  inhibiting 
BFA-induced redistribution of Golgi proteins into the ER. 
Rapid Reformation of the Golgi Apparatus in 
BFA-treated Cells Exposed to Forskolin 
We have shown in the above experiments thatcells prein- 
cubated with forskolin can be protected from the effects of 
BFA. To determine what effect, if any, forskolin has on the 
distribution of Golgi proteins in  cells already exposed to 
BFA, we treated cells with BFA for 1 h at 37°C to disassem- 
ble the Golgi apparatus and then added forskolin for various 
times (Fig. 6). In the presence of BFA alone Man H staining 
was diffusely distributed in punctate structures characteristic 
of  its distribution in the ER while the 110-kD protein was dis- 
persed throughout the cytoplasm. No colocalization  between 
the two markers was observed. Addition of forskolin, how- 
ever, changed this. Within 30 min, Man II and the ll0-kD 
protein appeared colocalized in discrete vesicles throughout 
the cytoplasm of most cells.  These vesicles became larger 
with time, collecting at a perinuclear location. By 2 h in the 
presence of forskolin plus BFA, both Man II and the ll0-kD 
protein colocalized in  structures  resembling  an untreated 
Golgi apparatus. In control cells treated with BFA only, Man 
H immunofluorescence retained its ER pattern distinct from 
the diffuse distribution of the 110- kD for the duration of the 
study (not shown). 
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induced dispersal of the Golgi apparatus. NRK cells were treated 
with BFA (0.1 ~g/ml) for 1 h (A); with forskolin (100 ttM) for 30 
min and then forskolin plus BFA (0.2/~g/ml)  for 1 h (B); with 
dibutyryl cAMP (10/~M) for 10 rain and then dibutyryl cAMP plus 
BFA (0.1 ttg/ml) for 1 h (C); with 1,9 dideoxyforskolin (100 I~M) 
for 30 rain and then 1,9 dideoxyforskolin plus BFA (0.1/~g/ml) for 
1 h (D); with 6-HPP-forskolin (100 ttM) for 30 rain and the 6-HPP- 
forskolin plus  BFA (0.1 ttg/ml)  for  1 h  (E);  and  with  7-HPP- 
forskolin (100 ttM) for 30 rnin and then 7-HPP-forskolin  plus BFA 
(0.1 t~g/ml) for 1 h (F). The cells were then fixed, permeabilized 
and stained for immunofluorescence using antibodies to Man I1. 
After treatment of cells with BFA alone for 1 h (,4), Man n  was 
distributed in a punctate pattern that is characteristic of  its distribu- 
tion in the ER and associat~ vesicles. In cells treated with forskolin 
before the addition ofBFA (B), Man II appeared only in juxtanu- 
clear Golgi structures essentially indistinguishable from its distri- 
bution  in control cells.  Raising intracellular  cAMP levels with 
dibutyryl cAMP before the addition of BFA (C) had no inhibitory 
effect on BFA-induced redistribution of Man II into the ER. Treat- 
ment with either 1,9 dideoxyforskolin (D) or 7-HPP-forskolin  (F), 
however, prevented BFA-induced  disassembly of the Golgi appara- 
tus while treatment with 6-HPP-forskolin  did not (E). These results 
suggest forskolin's ability to inhibit BF~Cs effects on the Golgi ap- 
paratus exhibits specificity for forskolin structure and occurs by a 
cAMP independent mechanism. Bar, 10 t~m. 
The process of Golgi recovery after addition of forskolin 
to BFA-treated cells was  nearly indistinguishable from the 
sequence of events observed previously for the reassembly 
of the Golgi apparatus upon removal of BFA (see Lippincott- 
Schwartz et al.,  1990, and Donaldson et al.,  1990). In both 
recovery processes, the 110-kD protein rapidly reassociated 
with Man II-containing vesicles that were scattered through- 
out the cytoplasm.  These vesicles  aggregated  into  larger 
structures with time and then migrated into a juxtanuclear 
location to form elongated interconnected Golgi networks. 
These results suggest that forskolin can act to reverse BF~s 
effects on Golgi morphology. 
As demonstrated in the above experiment protein export 
from the ER occurs in BFA-treated cells exposed to forsko- 
lin. Whether protein export to more distal sites in the cell 
than the Golgi apparatus occurs under these conditions was 
tested by examining the rate of secretion of fibronectin in 
cells exposed to BFA or BFA plus forskolin (data not shown). 
In ceils treated with BFA alone, secretion of newly synthe- 
sized fibronectin was essentially undetectable at 100 ng/ml 
BFA over 3 h.  In cells exposed to forskolin (100 ~M) plus 
BFA (100 ng/ml):, however, secretion was deafly detected 
over this Same period. The rate of fibronectin secretion in 
cells treatexl with BFA plus forskolin was somewhat slower 
than untreated cells,  however.  This may be explained,  in 
part, by the fact that forskolin alone demonstrated slower 
rates of fibronectin secretion. These results indicate that for- 
skolin can reverse, at least partially,  the block in protein 
secretion induced by BFA. 
Forskolin Acts by a cAMP Independent 
Mechanism to Inhibit BFA-induced Redistribution of 
Golgi Membrane into the ER 
Forskolin has been studied most extensively for its effects on 
adenylyl cyclase, but has other effects on ceils as well (Lau- 
renza et al.,  1989; Seamon and Daly,  1986). To determine 
whether forskolin inhibition of BFA is related to increased 
cAMP levels that accompany forskolin stimulation of ade- 
nylyl cyclase we attempted to reproduce the effects of forsko- 
lin by incubation with dibutyryl cAMP, a  membrane per- 
meant analogue of cAMP that has been used previously to 
raise intracellular cAMP levels (Nigg et al., 1985). Preincu- 
bation with  10 mM dibutyryl cAMP, however, had essen- 
tially no effect on the redistribution of Golgi membrane in- 
duced by BFA (Fig. 7 C). Similar results were obtained with 
8-bromo-cAMP (data not shown). Pretreatment of  cells with 
0.5 mM isobutyl methylxanthine (IBMX), a potent inhibitor 
of cAMP phosphodiesterase also  had no inhibitory effect 
upon BFA-induced movements and did not potentiate the in- 
hibitory effects of forskolin (data not shown). The latter phe- 
nomenon, a result of forskolin's and IBMX's sYnergistic  ef- 
fects on the accumulation of intracellular cAMP, has been 
observed for a number of cAMP-dependent phenomena (For- 
scher et al.,  1987). 
Forskolin  analogues  with  differing  potencies  towards 
adenylyl cyclase (see Fig. 8) were tested for their abilities to 
inhibit BF~s effects. 1,9-Dideoxyforskolin is a naturally oc- 
curring analogue of forskolin that does not activate adenylyl 
cyclase and reproduces many of the cAMP independent ef- 
fects of forskolin (Laurenza et al.,  1989).  1,9-Dideoxyfor- 
skolin inhibited BFA-induced redistribution of Golgi pro- 
teins into the ER with a  similar potency as forskolin (Fig. 
7  D).  Another analogue, 7-HPP-forskolin, which is much 
less potent than forskolin at binding to adenylyl cyclase, also 
inhibited BFA-induced redistribution of Golgi proteins (Fig. 
7 F). In contrast, a similar analogue, 6-HPP-forskolin, which 
is equipotent with forskolin in binding to adenylyl cyclase, 
did  not  inhibit BFA-induced  Golgi  dispersal  (Fig.  7  E). 
These results are consistent with forskolin inhibiting BFA ac- 
tion by a cAMP independent mechanism that demonstrates 
specificity for different forskolin analogues. 
Discussion 
Perhaps  the  most  striking  characteristic  of the  secretory 
pathway is the dynamic nature of membrane traffic. Mem- 
brane and secretory proteins are known to move rapidly and 
selectively through different subcompartments of this path- 
way yet the identity and function of these compartments are 
maintained.  The  development of reversible  (temperature 
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sensitive) mutants of the secretory pathway (sec mutants) of 
Saccharomyces cerevisiae (Novick et al., 1980; Schekman, 
1985) has provided an important tool for the identification 
of specific biochemical components involved in the regula- 
tion of secretion. In these mutants, the ability to reversibly 
inactivate individual genes  and/or  gene products  has  re- 
vealed the crucial function of  particular proteins in the secre- 
tory system. More complex eukaryotic cells are, at present 
much less amenable to these sorts of genetic manipulations. 
However,  we  can  consider a pharmacologic analogue to 
these temperature-sensitive mutants that does  function in 
higher organisms. BFA is the first drug that can reversibly 
alter the normal membrane dynamics within the early secre- 
tory pathway.  Not only has  it been  a  useful tool for ex- 
perimentally manipulating protein and membrane movement 
through the secretory pathway but the striking changes in 
cells induced by BFA promise to reveal a variety of  processes 
that normally take place in the organelles of the early secre- 
tory pathway but are difficult to observe. Understanding the 
mechanism of action of BFA, therefore, will likely lead to 
the identification of critical molecules that control the struc- 
ture and function of one or more of the organdies of this 
pathway. 
The identification of drugs that can either mimic, enhance 
or antagonize BF,~s effects on cells could be of great use for 
identifying either BF,~s site of action or potentially to sepa- 
rate different effects of BFA. When two of us (J. Glickman 
and M. Sheetz) attempted to pharmacologically manipulate 
the effects of BFA on cells in culture, addition of forskolin 
to cells was observed to block the morphologic changes in 
the Golgi apparatus normally seen after the addition of BFA. 
Forskolin  was  tested  because  of  its  ability  to  activate 
adenylyl  cyclase and to thereby raise intracelhlar cAMP lev- 
els which was thought might alter BFb2s action. In the studies 
reported here with forskolin and forskolin derivatives, we 
have followed the fate of Golgi components using a  lipid 
marker of  the Golgi apparatus, NBD-ceramide, antibodies to 
a cis/medial Golgi marker, Man II, and antibodies to a Golgi 
peripheral membrane protein of 110 kD. 
Observable effects of BFA on the Golgi apparatus follow 
a temporal pattern that is first detected within 30 s after addi- 
tion of BFA when the ll0-kD Golgi peripheral membrane 
protein dissociates from the Golgi apparatus into a diffuse 
cytosolic distribution (Donaldson et al., 1990).  This is fol- 
lowed by the movement of Golgi membrane proteins into 
long tubular processes which over time fuse with the ER 
resulting  in  the  mixing  of Golgi  proteins  with  the  ER 
(Lippincott-Schwartz et al.,  1990).  The  fluorescent lipid 
marker of the Golgi apparatus N-BD-ceramide,  examined in 
this study in living cells and in a previous study in fixed cells 
(Young et al., 1990), followed this temporal pattern of move- 
ment in the presence of BFA further suggesting there is a 
nonselective, likely complete breakdown of the Golgi ap- 
paratus in response to BFA. 
All  of the  above  mentioned effects of BFA  could  be 
abrogated by pretreating ceils with forskolin. This is in con- 
trast to other treatments that inhibit the redistribution of 
Golgi markers into the ER flow temperatures or nocodazole) 
but do not block the ability of BFA to induce the rapid redis- 
tribution into the cytosol of the ll0-kD protein (see Donald- 
son et al., 1990).  Thus, we cannot distinguish the morphol- 
ogy of a cell that has been exposed to forskolin plus BFA 
from that of an untreated cell. 
In addition to forskolin's ability to inhibit BF~s morpho- 
logical effects on the Golgi apparatus,  forskolin also ap- 
peared to be able to reverse BF,~s functional effects on pro- 
tein  secretion.  In  cells  exposed  to  BFA  plus  forskolin, 
protein  secretion occurred.  This  was  in contrast to  cells 
treated with BFA alone, where protein secretion was unde- 
tectable over 3 h of drug treatment. 
Forskolin's ability to inhibit BF~s effects extended to other 
phases of BFA treatment. Thus, if forskolin was added to 
cells after BFA had been added and at any point after BF~s 
morphologic changes in the cell had been established, the re- 
sult was a complete reversal in the morphology of the cell 
to an untreated state. These events closely resembled those 
after removal of BFA.  Although the effects observed upon 
removing BFA could be the result of the rapid metabolic in- 
activation of BFA, we think that it more likely reflects the re- 
versible binding of  BFA to its celhilar target(s). If  this is true, 
then forskolin's ability to reverse BF,~s effects is consistent 
with its binding to the same cellular target(s) as BFA. 
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its ability to activate  adenylyl cyclase; subsequent examina- 
tion however, clearly dissociated its activity from alterations 
in cellular cAMP  levels.  Two membrane permeable ana- 
logues of cAMP were unable to mimic the effects of forsko- 
lin. Furthermore,  the addition of a phosphodiesterase inhibi- 
tor, IBMX, did not potentiate the action of forskolin or reveal 
effects due to the cAMP analogues. 
It is known that forskolin has effects other than the activa- 
tion of adenylyl eyclase (Laurenza et al., 1989). Thus forsko- 
lin has been reported to inhibit the glucose transporter,  the 
multidrug resistance gene product and a variety of gated ion 
channels (Kashiwagi et al.,  1983; Coombs and Thompson, 
1987).  The  synthesis  of a  variety  of forskolin derivatives 
(Robbins, J., A. Lanrenza, G. O. O'Malley,  B. Spahl, R. W. 
Kosley,  and K. B. Seamon, manuscript submitted for publi- 
cation) has proven useful in delineating the different cellular 
effects of forskolin.  Many  of these derivatives demonstrate 
only selective cellular actions. To further define the mecha- 
nism by which forskolin inhibits BE~s cellular effects, there- 
fore, we used several  of these in our studies (Fig.  8).  1,9- 
Dideoxyforskolin  does  not  activate  adenylyl  cyclase  and 
7-HPP-forskolin is not potent at binding to adenylyl cyclase. 
However, both analogues were equally effective as forskolin 
at antagonizing BFA. In contrast, 6-HPP-forskolin, which is 
equipotent  with  forskolin  at  binding  to  adenylyl  cyclase, 
showed essentially no ability to antagonize BFA.  Taken to- 
gether,  these data rule out almost any role of cAMP in an- 
tagonizing the effects of BFA in cells. Furthermore, the abil- 
ity  of the  7-HPP-forskolin but not the 6-HPP-forskolin to 
antagonize BFA implicates specific structural  determinants 
in forskolin activity. 
All of these observations are consistent with forskolin act- 
ing as a competitive antagonist of BFA. This was further sup- 
ported  by  dose-response  competitions  between  the  two 
drugs.  Either of the drugs can overcome the effects of the 
other simply by raising the dose of drug added.  Thus, the 
dose-response curve for BFA is shifted progressively by in- 
creasing the concentration of added forskolin. Despite these 
observations,  we do not know whether forskolin is indeed 
a competitive antagonist of BFA at the molecular level. Es- 
tablishing this will require the demonstration that it binds to 
the same cellular target(s) as BFA. Although we currently fa- 
vor this interpretation,  other e~planations are possible. For- 
skolin could be acting to "inactivate" BFA, either by inducing 
its metabolism or altering its access to the cell. However we 
would riot exl~ect this mechanism to generate simple sym- 
metric shifts in dose response curves. Alternatively,  forsko- 
lin could be "activating" a molecular target whose action is 
to antagonize the effects of BFA. According to this interpre- 
tation, forskolin would be activating an antagonistic pathway 
but would not be interacting  with the same molecular target 
as BFA. 
An interesting question raised by  forskolin's  interaction 
with BFA, regardless of the molecular mechanism, is whether 
forskolin is a pure antagonist or whether it exerts indepen- 
dent effects of the structure and function on the Golgi appara- 
tus.  Although no distinct morphologic effects on the Golgi 
apparatus by forskolin alone have been observed, other pos- 
sible effects on the Golgi system by this drug are being inves- 
tigated.  The availability of functional derivatives of forskolin 
which can be used for covalent affinity labeling promises to 
provide new tools for establishing the molecular basis for 
how BFA and forskolin together can regulate the identity and 
function of an intracellular organelle. 
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